[EN] 2-CYANOPYRROLES AND THEIR ANALOGUES AS DDP-IV INHIBITORS<br/>[FR] 2-CYANOPYRROLES ET LEURS ANALOGUES EN TANT QU'INHIBITEURS DE DIPEPTIDYLPEPTIDASE-IV (DP-IV)
申请人:NOVO NORDISK AS
公开号:WO2004089362A1
公开(公告)日:2004-10-21
The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV having the formula I: (I) The invention furthermore relates to pharmaceutical compositions comprising the compounds and the use of such compounds for the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity.
A C-terminal amidothiourea motif is shown to promote a β-turn-like folded conformation in a series of β-amino acid-based short peptides in both the solidstate and solution phase by an intramolecular 11-membered ring hydrogen bond.
Configurationally Stable (<i>S</i>)- and (<i>R</i>)-α-Methylproline-Derived Ligands for the Direct Chemical Resolution of Free Unprotected β<sup>3</sup>-Amino Acids
作者:Shengbin Zhou、Shuni Wang、Jiang Wang、Yong Nian、Panfeng Peng、Vadim A. Soloshonok、Hong Liu
DOI:10.1002/ejoc.201800120
日期:2018.4.23
A series of nonracemizable ligands are synthesized for the direct chemical resolution of various unprotected β3‐amino acids with high enantioselectivity and yields. One of the obtained free enantiomerically pure β‐amino acids can be applied directly as a starting material for the synthesis of the anti‐HIV drug maraviroc in an overall yield of 49 % in six steps.
[EN] INHIBITORS OF JANUS KINASES<br/>[FR] INHIBITEURS DE JANUS KINASES
申请人:MERCK & CO INC
公开号:WO2009075830A1
公开(公告)日:2009-06-18
The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.